AnaptysBio, Inc. ANAB
Regular-session close
After hours · Nov 20, 4:38 PM ET
- YTD
- +44.28%
- 1 year
- +85.70%
5D +0.62 (+1.35%)
- Market cap
- 1.39B
- Revenue (ttm)
- 60.04M
- Profit margin
- 417.63%
- EPS (ttm)
- 6.52
- Shares out
- 29.73M
- P/E ratio
- 7.15
- Forward P/E
- 8.65
- YTD return
- +44.28%
- 1-year return
- +85.70%
- 50-day average
- 49.02
- Volume
- 432.45K
- Avg volume
- 495.13K
- Open
- 46.63
- Previous close
- 47.40
- Day's range
- 46.05 – 47.66
- 52-week range
- 25.11 – 69.81
- Beta
- 0.37
- Analysts
- Strong Buy
- Price target
- 87.25 (+87.1%)
- Earnings date
- Mar 2, 2027
Key statistics
- 200-day average
- 51.47
- Enterprise value
- 1.52B
- Price / sales
- 23.08
- Price / book
- 67.06
- Revenue growth
- -60.30%
- Total cash
- 152.99M
- Total debt
- 262.39M
- Short % of float
- 37.03%
Fundamental scorecard
9 of 25 checks passed on ANAB’s reported financials
9of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 2 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 60.00
- Target (mean)
- 87.25
- Target (high)
- 140.00
- Strong buy3
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 2, 2027
Expected Mar 2, 2027. Consensus EPS estimate 1.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 2, 2027 | Dec 30, 2026 | 0.54 | — | — | — |
| Nov 12, 2026 | Sep 30, 2026 | -1.84 | 0.11 | +1.95 | +105.98% |
| Sep 21, 2026 | Jun 30, 2026 | 5.11 | 5.11 | 0.00 | 0.00% |
| May 12, 2026 | Mar 31, 2026 | -0.32 | -1.84 | -1.52 | -475.00% |
| Mar 3, 2026 | Dec 31, 2025 | 0.89 | 1.58 | +0.69 | +77.53% |
| Nov 4, 2025 | Sep 30, 2025 | -1.06 | 0.52 | +1.58 | +149.06% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Sep 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 23, 2026 | Leerink Partners | main | Outperform | Outperform |
| Aug 25, 2026 | TD Cowen | main | Buy | Buy |
| Aug 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 13, 2026 | UBS | main | Buy | Buy |
About AnaptysBio, Inc.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anaptysbio.com
News
Your note
Sign in to keep a note on ANAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 17, 2026 | 0 |
| FAGA DANIEL R | Chief Executive Officer | Sale | Mar 26, 2026 | 495,965 |
| JAIN RITA | Director | Conversion of Exercise of derivative security | Jun 12, 2025 | 11,864 |
| LIZZUL PAUL F. | Officer | Sale | Jan 7, 2026 | 42,088 |
| LOUMEAU ERIC JOSEPH | Officer | Sale | Feb 10, 2026 | 12,835 |
| MARQUET MAGDA | Director | Sale | Jan 14, 2026 | 9,930 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 26.51% | 7,880,094 | 367.29M | Sep 29, 2026 |
| Blackrock Inc. | 6.36% | 1,891,512 | 88.16M | Sep 29, 2026 |
| Tang Capital Management, LLC | 4.96% | 1,474,262 | 68.72M | Sep 29, 2026 |
| State Street Corporation | 3.85% | 1,145,901 | 53.41M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 3.06% | 909,946 | 42.41M | Sep 29, 2026 |
| Goldman Sachs Group Inc | 2.86% | 850,343 | 39.63M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.18% | 648,146 | 30.21M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.15% | 640,363 | 29.85M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.76% | 522,209 | 24.34M | Sep 29, 2026 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 0.89% | 263,840 | 12.30M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.80% | 237,032 | 11.05M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.73% | 215,697 | 10.05M | Sep 29, 2026 |
